Cann Global Ltd(CGB:AX) is an Australian Medical Cannabis and Hemp Foods company focusing on research, cultivation/harvesting and manufacturing of consumables
Don't forget to drop in to our online webcast today, where we will present our half-year results and an update on our operations. Link below 👇
URL: https://t.co/58QH2Z1c3C
Date: Monday 7 March 2022
Time: 3:00pm AEDT
@CGBCannGlobal releases its Activities Report & Quarterly Cash Flow Statement (Appendix 4C) for the quarter ending 31 March 2021 (Q3 FY2021).
Get up to date with our vision and plans for the future.
See the full report: https://t.co/8RjKw2koCu
Cann Global (CGB) has entered a binding agreement with Western Sydney University’s NICM Health Research Institute.
https://t.co/s6EIWt3LET
#themarketherald#asxnews $CGB $CGB.AX
Export permit granted for Canntab's patented cannabis hard pill
Following the export permit being issued, Cann advises that its order of the hard pill products will begin arriving in Australia next month.
Read the full article on The Market Herald https://t.co/HQCMSsckF1
#CGB
“So where do we see ourselves in five years? I don’t see any reason why we shouldn’t be a multi-billion dollar company in five years’ time. That’s not to give investment advice, that’s just where I see it.” https://t.co/9zdvrmKzDb
Cann Global Posts Half Yearly Accounts
Revenue for HY21 up 29% increase on the prior comparable period (pcp) and an increase of 15% over H2FY20, largely due to continued strong sales in plant-based food products.
Read the full release here: https://t.co/Wz8v9IHEcA
Our JV partner @Canntab_ has just been granted a second patent on its hard pill formulations that will land in Australia via Cann Global. The patent confirms Canntab formulations are unique and differentiated from other products in the global marketplace. #pharmaceuticalgrade
Cann Global $CGB has revealed it will be undertaking a share placement to raise $3.75 million.
The company entered a trading halt on Monday but did not reveal how much it would be raising or what it would be using the money for.
Read the news here: https://t.co/Mnua6EOZtI
Cann Global Limited has entered a #trading halt in ahead of an upcoming #capital raise.
The company is yet to announce how much it is aiming to raise or what it will use the #funds for.
Read the full article on The Market Herald >>>
https://t.co/C9mLRJWDq4
#markets#asx
Australia is primed to get access to Cann's product range through a joint venture deal with Canada-based Canntab Therapeutics signed in January 2018.
https://t.co/tSEaua9Zln
Cann Global (ASX:CGB): Disrupting the lucrative #Australian cannabis market.
Read just how $CGB is paving the way with its range of cannabis products below on @themarketherald >>>
https://t.co/tSEaua9Zln
#hemp#food#cannabis#cbd#healthcare#products#retail
Cann Global $CGB is pleased to release the Q1FY20 #Quarterly Activities and Cashflow #Report, covering all the #success for the company so far and a healthy cash balance moving forward of $8.9m-CGB is positioned well to continue its #growth.
Full report: https://t.co/R92BmZJ7Ks
@CGBCannGlobal Your company was featured in today’s Potcasts Cannabis Newsletter/Podcast
Check it out https://t.co/1FhKqKDPlL
Feel free to share this on all your social media profiles
If you want to learn more about us visit https://t.co/8d7pWrN3Dk
Or call us at 800 665 0411
@CGBCannGlobal's #CEO Sholom Feldman and Canntab Therapeutics Ltd.'s #CFO Richard Goldstein discuss #Canntab sales in Australia, and the future of this deal in Australia.
Watch the full interview below >>>
https://t.co/SjflqxWSF6
#asx#news#finance#medicine#healthcare